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Neonatal sepsis causes significant mortality and morbidity worldwide. Diagnosis is usually
confirmed via blood culture results. Blood culture sepsis confirmation can take days
and suffer from contamination and false negatives. Empiric therapy with antibiotics is
common. This study aims to retrospectively describe and compare treatments of blood
culture-confirmed and unconfirmed, but suspected, sepsis within the University of Utah
Hospital system. Electronic health records were obtained from 1,248 neonates from
January 1, 2006, to December 31, 2017. Sepsis was categorized into early-onset (≤3
days of birth, EOS) and late-onset (>3 and ≤28 days of birth, LOS) and categorized as
culture-confirmed sepsis if a pathogen was cultured from the blood and unconfirmed if all
blood cultures were negative with no potentially contaminated blood cultures. Of 1,010
neonates in the EOS cohort, 23 (2.3%) were culture-confirmed, most with Escherichia
coli (42%). Treatment for unconfirmed EOS lasted an average of 6.1 days with primarily
gentamicin and ampicillin while confirmed patients were treated for an average of 12.3
days with increased administration of cefotaxime. Of 311 neonates in the LOS cohort, 62
(20%) were culture-confirmed, most culturing coagulase negative staphylococci (46%).
Treatment courses for unconfirmed LOS lasted an average of 7.8 days while confirmed
patients were treated for an average of 11.4 days, these patients were primarily treated
with vancomycin and gentamicin. The use of cefotaxime for unconfirmed EOS and LOS
increased throughout the study period. Cefotaxime administration was associated with
an increase in neonatal mortality, even when potential confounding factors were added
to the logistic regression model (adjusted odds ratio 2.8, 95%CI [1.21, 6.88], p = 0.02).
These results may not be generalized to all hospitals and the use of cefotaxime may be
a surrogate for other factors. Given the low rate of blood culture positive diagnosis and
the high exposure rate of empiric antibiotics, this patient population might benefit from
improved diagnostics with reevaluation of antibiotic use guidelines.
Keywords: neonatal sepsis, antibiotic stewardship, rational prescribing, empiric therapy, newborns, bloodstream
infections
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INTRODUCTION

severe congenital neutropenia, Shwachman-Diamond syndrome,
and Kostmann syndrome) were excluded from data collection.
We categorized these patients as suspected early-onset
sepsis (EOS) when any blood culture was drawn and antibiotics
were initiated ≤3 days of birth and suspected late-onset sepsis
(LOS) when any blood culture was drawn and antibiotics were
administered >3 but ≤28 days of birth and ≥7 days after a positive
blood culture associated with confirmed EOS. Neonates with
suspected late or early-onset sepsis are not mutually exclusive,
that is, a single neonate can be categorized as both suspected
early and late-onset sepsis if it meets the criteria for both.
Neonates suspected of having sepsis were further divided into
two categories, confirmed sepsis and unconfirmed sepsis. These
categories are mutually exclusive (i.e., a single neonate suspected
of having LOS must be either confirmed or unconfirmed LOS).
Only blood cultures were used to confirm neonatal sepsis.
Centers for Disease Control and Prevention (CDC) bloodstream
infection criteria were adapted for use to confirm sepsis with some
modifications (Horan et al., 2008). According to these guidelines,
if there was a recognized pathogen in a blood culture, sepsis was
confirmed. If a common skin contaminant was cultured, and the
organism was cultured again in the following 48 h, sepsis was
also confirmed. If a common skin contaminant was cultured, and
the organism was not cultured again in the following 48 h, then
these cultures were possibly contaminated and these patients
were excluded from analysis as ambiguous cases. The following
microorganisms were considered common skin contaminants:
diphtheroids, Bacillus spp., Micrococcus spp., non-pathogenic
Neisseria spp., gram-positive rods, coagulase negative
staphylococci (CoNS), and non-pathogenic streptococcal species
(e.g., Streptococcus viridans) (Hall and Lyman, 2006). We also
analyzed cerebrospinal fluid (CSF) cultures.
Antibiotic exposure was measured by days of treatment
(DOT) and length of treatment (LOT) (Ibrahim and Polk,
2014). DOT is measured by multiplying the number of doses
by the dosing interval in days for each antibiotic administered.
DOT is normalized to per 1,000 patient days (PD) which is the
mean length of stay multiplied by 1,000. LOT is measured by the
number of calendar days a patient received any antibiotic. LOT
is normalized to per admission and per treatment course. LOT/
course is equivalent to the mean number of days that neonates
are treated for an episode of sepsis. Antibiotics administered
topically were not included.
Treatment courses were calculated as continuous periods of
antibiotic exposure with no gap in administration greater than
or equal to two calendar days to accommodate for extended
intervals of aminoglycoside dosing in extremely low birthweight
newborns. In some cases, there was continuous administration of
antibiotics from within three days of birth to well beyond three
days after birth where there was an obvious switch from treatment
of unconfirmed EOS to treatment of suspected LOS. For example,
in one neonate, a negative culture was drawn on day one of life
and ampicillin and gentamicin were administered as treatment
for EOS. At day five of life, more cultures were drawn, ampicillin
administration ceased, and vancomycin administration began
as treatment for LOS. In these cases, we considered treatment
courses ending for EOS and treatment courses beginning for

Neonatal sepsis remains a significant cause of morbidity and
mortality, particularly among preterm and low birth-weight
neonates (Thaver and Zaidi, 2009; Shane et al., 2017). It is
estimated that within 28 days of birth, 13% of neonatal mortality
worldwide is caused by sepsis or meningitis (Liu et al., 2012).
Neonatal sepsis is commonly divided into early-onset sepsis
(EOS) and late-onset sepsis (LOS). EOS (≤3 days of birth) is
generally associated with organisms transferred to the neonate
from the mother while LOS (>3 days of birth) is usually associated
with nosocomial or community acquired infections (Dong and
Speer, 2015).
Diagnosing neonatal sepsis can be enigmatic—there is no
consensus among clinicians or researchers. The current “gold
standard” for diagnosis is a positive blood culture (Wynn
et al., 2014). Blood culture-confirmed sepsis is only one facet
of the disease; suspected sepsis in culture-negative cases is still
considered clinical sepsis (Lukacs and Schrag, 2012; Wynn
et al., 2014). Current recommendations call for empiric use of
antibiotics before culture confirmation if sepsis is suspected,
and possible continued antibiotic treatment if signs of sepsis
persist when the culture is negative (Camacho-Gonzalez et al.,
2013; Shane et al., 2017). Because of this approach, antibiotics
are frequently administered in neonatal intensive care units
(NICUs). In a study of 253,651 NICU neonatal records within
the Pediatrix Medical Group database, the two most commonly
administered drugs were ampicillin (69%) and gentamicin
(58%); additionally, 18% of neonates were exposed to cefotaxime
and 10% to vancomycin (Clark et al., 2006). With an increasing
emphasis on antibiotic stewardship, it is essential to understand
how neonatal sepsis is confirmed and treated, and to identify
opportunities for reducing antibiotic use.
A retrospective analysis was conducted using data obtained
from The University of Utah Health system, comprising
four hospitals and 12 community clinics. Our objective was
to thoroughly describe the blood culture confirmation and
antibiotic treatment of neonatal sepsis within this hospital system.
Antibiotics used to treat culture confirmed and unconfirmed
sepsis are compared for both early and late onset sepsis over a
12-year period.

Methods

Collection of medical records for analysis was approved by the
University of Utah Institutional Review Board (IRB_00091312).
Records were collected from neonates born and/or admitted to
the University of Utah Hospitals within 28 days of birth between
January 1, 2006, and December 31, 2017, with ICD9 billing code
771.81 or ICD10 code P36 (newborn sepsis). Neonates with major
birth defects such as spina bifida, gastroschisis, congenital heart
defects (excluding patent ductus arteriosus and patent foramen
ovale), Down syndrome, encephalocele, and microcephaly
or neonates born from mothers with a family history of
congenital immune disorders (x-linked agammaglobulinemia,
x-linked neutropenia/myelodysplasia, common variable
immunodeficiency, severe combined immunodeficiency,
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and 311 met inclusion criteria for the LOS cohorts (Figure 1).
Patient demographics, mortality rate, length of stay, severity of
illness, risk of mortality, birth weight, and gestational age for
each cohort are compared in Table 1. Confirmed cases of LOS
were more likely to include neonates with lower gestational age,
lower birth weight, and higher severity of illness than neonates in
unconfirmed cases of LOS (p < 0.01).
Documentation about the source of the blood for the cultures
was limited and unclear in many cases, but at least 10% were
catheter-drawn, and at least 40% of those did not have an
additional percutaneous culture within ±48 h. After the first
positive culture in confirmed cases, the median interval between
subsequent cultures was 0.98 days IQR [0.62, 1.48]. Additionally,
there were 389 CSF cultures drawn within 28 days of birth in
this study cohort. Two neonates had positive CSF cultures, these
are described below. Although most of the blood culture isolates
were bacteria, there were six neonates that were infected with
yeast. Three were infected with Candida lusitaniae, one with
Candida dubliniensis, and the species of the remaining two could
not be determined from the records.
Specific organisms associated with confirmed sepsis are
outlined in Table 2. Blood cultures that were drawn within

LOS when there was a blood culture drawn after three days of
birth, then a change in antibiotic regimen on or after the same
calendar day.
Severity of illness and risk of mortality were measured using All
Patient Refined Diagnosis Related Groups (APR-DRG). Univariate
comparisons were evaluated using Student’s t-test for continuous
variables and chi-squared test or Fisher’s exact test for categorical.
Median values are reported with an interquartile range (IQR) in
brackets and mean values are reported with standard deviation
(SD) in parenthesis. Trends over time were analyzed using simple
linear regression for continuous variables, logistic regression for
dichotomous variables, or one-way ANOVA for severity of illness
and risk of mortality. Statistical tests were considered significant
when p < 0.05. All analyses were undertaken with R version 3.5.3
(R Core Team, 2019) in conjunction with the dplyr version 0.8.0
R package.

RESULTS
A total of 1,248 neonates met inclusion criteria for data
collection, 1,010 met inclusion criteria for the EOS cohorts

FIGURE 1 | Flow chart of study cohort selection.
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TABLE 1 | Cohort demographics.
Early-Onset

Late-Onset

Unconfirmed

Confirmed

P value

Unconfirmed

Confirmed

P value

Number of cases
987
Mortality within 35 Days of Birth (%)
26 (2.6)
Length of Stay in Days (median [IQR])
23 [8, 57]
Risk of Mortality (%)
Extreme
118 (12.0)
Major
375 (38.0)
Moderate
231 (23.4)
Minor
255 (25.8)
Missing
8 (0.8)
Severity of Illness (%)
Extreme
319 (32.3)
Major
342 (34.7)
Moderate
223 (22.6)
Minor
95 (9.6)
Missing
8 (0.8)
Patients with other Positive Cultures within 28 Days of Birth
Lungs/Airway (%)
75 (7.6)
Urine (%)
34 (3.4)
Cerebrospinal Fluid (%)
3 (0.3)
Gestational Age (%)
>= 37 weeks (term)
272 (27.6)
32–37 weeks (preterm)
281 (28.5)
28–32 weeks (very preterm)
212 (21.5)
<28 weeks (extreme preterm)
222 (22.5)
Birth Weight (%)
>= 2.5 kg (normal)
332 (33.6)
1.5–2.5 kg (low)
275 (27.9)
1-1.5 kg (very low)
156 (15.8)
<1 kg (extremely low)
224 (22.7)
Male Gender (%)
535 (54.2)
Race (%)
White or Caucasian
528 (53.5)
Asian
23 (2.3)
Black or African American
26 (2.6)
Pacific Islander
11 (1.1)
American Indian
12 (1.2)
Other
102 (10.3)
Unknown
285 (28.9)
Ethnicity (%)
Not Hispanic/Latino
479 (48.5)
Hispanic/Latino
173 (17.5)
Unknown
335 (33.9)

23
2 (8.7)
41 [15, 57]

0.27
0.50

249
10 (4.0)
58 [34, 101]

62
6 (9.7)
69 [23, 101]

0.14
0.72

2 (8.7)
13 (56.5)
5 (21.7)
3 (13.0)
0 (0.0)

0.46

50 (20.1)
134 (53.8)
38 (15.3)
24 (9.6)
3 (1.2)

14 (22.6)
36 (58.1)
7 (11.3)
3 (4.8)
2 (3.2)

0.46

11 (47.8)
8 (34.8)
2 (8.7)
2(8.7)
0 (0.0)

0.42

134 (53.8)
88 (35.3)
14 (5.6)
10 (4.0)
3 (1.2)

45 (72.6)
12 (19.4)
2 (3.2)
1 (1.6)
2 (3.2)

0.04

2 (8.7)
0 (0.0)
1 (4.3)

0.12

40 (16.1)
25 (10.0)
4 (1.6)

18 (29.0)
6 (9.7)
1 (1.6)

0.57

4 (17.4)
7 (30.4)
5 (21.7)
7 (30.4)

0.68

14 (5.6)
46 (18.5)
75 (30.1)
114 (45.8)

1 (1.6)
4 (6.5)
15 (24.2)
42 (67.7)

<0.01

4 (17.4)
6 (26.1)
7 (30.4)
6 (26.1)
14 (60.9)

0.18

19 (7.6)
52 (20.9)
61 (24.5)
117 (47.0)
118 (47.4)

2 (3.2)
6 (9.7)
9 (14.5)
45 (72.6)
33 (53.2)

<0.01

11 (47.8)
0 (0.0)
0 (0.0)
1 (4.3)
0 (0.0)
3 (13.0)
8 (34.8)

0.68

140 (56.2)
3 (1.2)
8 (3.2)
6 (2.4)
2 (0.8)
28 (11.2)
62 (24.9)

35 (56.5)
1 (1.6)
0 (0.0)
1 (1.6)
1 (1.6)
4 (6.5)
20 (32.3)

0.58

6 (26.1)
9 (39.1)
8 (34.8)

0.51

138 (55.4)
39 (15.7)
72 (28.9)

26 (41.9)
13 (21.0)
23 (37.1)

0.16

0.50

as unconfirmed (Figure 1). There were 24 culture isolates
identified that were associated with EOS (Table 2); 1 of 23
(4.3%) neonates with confirmed EOS had more than one type
of non-contaminant organism (Escherichia coli with yeast).
The most common organisms identified as EOS pathogens
were Escherichia coli (43.5% of neonates) and group B
streptococcus (17.4%). One confirmed EOS patient infected
with Escherichia coli had both blood and CSF cultures positive
for Escherichia coli.
The ratio of culture confirmed to unconfirmed EOS
cases remained consistent over time (p = 0.59). Because of
the low number of confirmed EOS cases and the consistent
occurrence, trends over time were analyzed for the combined
confirmed and unconfirmed EOS cohorts. There was no
statistically significant change in severity of illness and risk

28 days of birth in all sepsis cohorts numbered 2,483;
within these, 223 (8.98%) contained organisms considered
as pathogens and 118 (4.75%) cultures were identified as
possibly contaminated. Of the cultures that were possibly
contaminated, 21 (17.8%) did not have a second blood culture
draw within ±48 h. Of the organisms identified as possible
contaminants, only coagulase-negative staphylococci (CoNS)
was also identified as a potential pathogen. Out of 226 cultures
that were positive for CoNS, 122 (54.0%) were categorized as
pathogenic.

Early-Onset Sepsis

There were 1,010 neonates within the EOS cohorts, 23 (2.3%)
were classified as confirmed cases of EOS and 987 (97.7%)
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3 days of birth for a mean of 11.8 days LOT, SD (6.0). Gram
negative microorganisms were cultured in 13 of the 15 confirmed
EOS patients treated with cefotaxime and two of the patients died
during the course of treatment.
There was no statistically significant changes in EOS course
LOT over the study period for both unconfirmed and confirmed
EOS (p = 0.45, 0.24 respectively). There was no significant
change in the rates of administration of any antibiotic for
confirmed EOS. Unconfirmed EOS courses saw a reduction in
the rate of gentamicin administration and an increase in the rate
of cefotaxime administration where very few courses included
cefotaxime in at the beginning of the study period, to nearly 30%
of courses including cefotaxime at the end of 2017 (Table 4).

TABLE 2 | Pathogens identified in culture-confirmed sepsis.
Organism

Gram-positive bacteria
CoNS
Enterococcus spp.
Staphylococcus aureus
Group B Streptococcus
Listeria monocytogenes
Streptococcus pneumoniae
Gram-negative bacteria
Escherichia coli
Klebsiella pneumoniae
Enterobacter spp.
Serratia marcescens
Haemophilus influenzae
Acinetobacter sp.
Citrobacter sedlakii
Neisseria meningitidis
Yeast

Early-onset sepsis*
(%)
n = 24

Late Onset sepsis*
(%)
n = 68

1 (4.2)
1 (4.2)
4 (16.7)
1 (4.2)
1 (4.2)

31 (45.6)
7 (10.3)
7 (10.3)
N/D
N/D
N/D

10 (41.7)
2 (8.3)
N/D
N/D
2 (8.3)
N/D
N/D
1 (4.2)
1 (4.2)

9 (13.2)
3 (4.4)
2 (2.9)
2 (2.9)
N/D
1 (1.5)
1 (1.5)
N/D
5 (7.4)

Late-Onset Sepsis

Of 311 neonates within the LOS cohorts, 62 (19.9%) were classified
as confirmed cases of LOS, 249 (80.1%) as unconfirmed. A total
of 68 culture isolates were identified as pathogens associated
with LOS (Table 2); 4 of 62 (6.5%) confirmed LOS neonates were
positive for multiple organisms (fist patient—CoNS, Klebseilla
pneumonia, Entercoccus faecalis, and Candida lusitaniae;
second—Staphylococcus aureus and Enterococcus faecalis; third—
CoNS and Acinetobacter sp.; fourth—Staphylococcus aureus
and Staphylococcus epidermidis). The most common pathogens
causing LOS were CoNS (50.0% of neonates) followed by
Escherichia coli (14.5%). One of the unconfirmed LOS neonates
had one positive CSF culture within >3–28 days of birth which
isolated Candida dubliniensis, no blood cultures were drawn
within ±4 days of this CSF culture.
Similar to confirmation rates in EOS, the ratio of culture
confirmed to unconfirmed LOS cases also remained consistent
over time (p = 0.80). There was no statistically significant change
in severity of illness, risk of mortality, gestational age, birth
weight, and length of stay over time when unconfirmed and
confirmed LOS were analyzed both combined and separated.
Mortality rates within 35 days of birth increased over time for
unconfirmed LOS (odds ratio 1.37/year, 95%CI [1.10, 1.81], p =
0.01) and confirmed LOS (odds ratio 1.42/year, 95%CI [1.06,
2.17], p = 0.04).
The most common antibiotics used in neonates with
unconfirmed and confirmed LOS were vancomycin and gentamicin
(Figures 2C–D). Similar to neonates with EOS, confirmed LOS
neonates had more exposure to antibiotics than unconfirmed
LOS by all metrics (Figure 2C, Table 3, p < 0.01). For courses
starting within >3–28 days of birth, rifampin was more frequently

*Number of unique patient-organism combinations. (A patient may have cultured more
than one organism.); N/D, not detected.

of mortality over time. The average gestational age and birth
weight for EOS neonates increased over the study period from
30.4 to 34.5 weeks and 1.50 to 2.45 kg respectively (R2 = 0.05,
p < 0.01 for both). The average length of stay for EOS neonates
decreased from of 45.9 days at the beginning of the study
period to 32.8 days at the end (R2 = 0.05, p < 0.01). Logistic
regression showed that there was a statistically significant
increase in the rate of mortality over time for EOS neonates
(odds ratio 1.27/year, 95%CI [1.10, 1.49], p < 0.01).
Confirmed EOS neonates had more exposure to antibiotics
than unconfirmed EOS neonates by all metrics in Table 3
(p < 0.01). Unconfirmed EOS neonates were mostly prescribed
ampicillin and gentamicin (Figure 2B); 77.2% of the LOT for
courses starting within 3 days of birth in these patients included
both ampicillin and gentamicin in combination. Confirmed EOS
neonates were treated with only one antibiotic more often than
unconfirmed EOS neonates (46.3% and 9.3% of LOT respectively,
Figure 2A). For confirmed EOS neonates, 65.3% of the LOT for
courses started within 3 days of birth included cefotaxime either
alone or in combination with other antibiotics, 35.1% consisted of
treatment with only cefotaxime. Cefotaxime was most common
antibiotic for confirmed EOS neonates (Figure 2B). Fifteen of
the confirmed EOS neonates received cefotaxime starting within

TABLE 3 | Measurements of total antibiotic exposure per cohort.
Metric

DOT/1000 PD (SD)
LOT/Admission (SD)
LOT/Course (starting ≤3 days of birth) (SD)
LOT/Course (starting >3–28 days of birth) (SD)

Early-Onset Sepsis*

Late-Onset Sepsis*

Suspected

Confirmed

Suspected

Confirmed

513 (477)
10.9 (10.0)
6.1 (3.4)
N/A

582 (334)
15.9 (7.0)
12.3 (6.2)
N/A

472 (314)
17.9 (11.5)
N/A
7.8 (5.7)

634 (385)
23.5 (14.9)
N/A
11.4 (9.4)

*The differences between suspected and confirmed sepsis were statistically significant for all metrics (p < 0.01).
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FIGURE 2 | Antibiotic use for treatment of neonatal sepsis. (A and C) number of antibiotics administered per calendar day as a percentage of LOT per cohort.
(B and D)—amount of each antibiotic administered as DOT/1,000 PD per cohort. (A and B) figures for early onset sepsis (EOS): only courses started within 3
days of birth are included. (C and D) figures for late onset sepsis (LOS): only courses started within >3–28 of birth were included.

TABLE 4 | Antibiotics with significant changes in administration rates over time. Results of logistic regression modeling with antibiotic administration rates at the
beginning and end of the time period (1/1/2006 - 12/31/2017).
Antibiotic

Unconfirmed Early Onset Sepsis
Cefotaxime
Gentamicin
Unconfirmed Late Onset Sepsis
Ampicillin
Cefotaxime
Gentamicin
Piperacillin-Tazobactam
Vancomycin
Confirmed Late Onset Sepsis
Gentamicin
Rifampin

Frontiers in Pharmacology | www.frontiersin.org

Odds ratio/year (95% CI)

P

Courses with Administration
Beginning

End

1.25 (1.17, 1.34)
0.69 (0.57, 0.80)

<0.01
<0.01

2.8%
99.8%

29.7%
87.2%

1.10 (1.02, 1.19)
1.24 (1.14, 1.37)
0.78 (0.70, 0.85)
1.24 (1.12, 1.39)
0.83 (0.75, 0.89)

0.02
<0.01
<0.01
<0.01
<0.01

28.9%
8.4%
92.4%
4.6%
86.8%

55.6%
55.8%
36.3%
39.8%
38.7%

0.78 (0.65, 0.91)
0.79 (0.65, 0.93)

<0.01
<0.01

94.0%
58.3%

42.8%
7.1%

6

October 2019 | Volume 10 | Article 1191

Wagstaff et al.

Treatment of Neonatal Sepsis

administered to confirmed LOS neonates than unconfirmed (41.2
and 2.6 DOT/1000 PD respectively, Figure 2D). In all 22 cases of
confirmed LOS treated with rifampin, the neonates were infected
with CoNS and treatment was always combined with vancomycin.
The mean time difference between the first positive culture draw
and the start of rifampin treatment was 4.0 days SD (1.8). In 17
neonates (77%), there were no positive cultures after initiation of
rifampin treatment, for the remaining neonates the mean time
to the last positive culture after treatment was started was 1.85
days SD (1.92). One patient died after 2.5 days of treatment with
rifampin; this patient had a positive culture drawn just prior to
death. There was no statistically significant changes in LOS course
LOT over the study period for both unconfirmed and confirmed
LOS (p = 0.93, 0.57 respectively). There was a reduction in the
rate of rifampin administration in cases of confirmed LOS, a
reduction in vancomycin administration for unconfirmed LOS,
and a reduction in gentamicin administration over time in both
cohorts (Table 4). Courses for unconfirmed LOS saw an increase
in the inclusion of ampicillin, piperacillin-tazobactam, and
cefotaxime (Table 4).

when treating chorioamnionitis or other maternal illnesses can
reduce sensitivity of blood cultures (Peralta-Carcelen et al.,
1996). To overcome these limitations, it is recommended that ≥
≥1 ml of blood is collected for culturing (Polin, 2012; Dien Bard
and McElvania TeKippe, 2016). Using 1 ml of blood for a blood
culture has been demonstrated to provide 98% sensitivity even
when pathogen concentrations are low (4 colony forming units
per ml) (Schelonka et al., 1996). The volume of cultured blood was
not available in this study, therefore the effect of blood volume on
false negative results in this hospital system are difficult to infer.
Even though a blood culture may provide a sensitive
diagnostic tool, the results may take several days. In the past,
attempts have been made to detect true cases of sepsis earlier
than a blood culture, (Philip and Hewitt, 1980) but there is no
consensus on how to incorporate laboratory tests in diagnosing
neonatal sepsis (Wynn et al., 2014). New biomarkers such as
bacterial surface antigens and emerging technologies such as
genetic sequencing based tools may be used more frequently
in neonatal sepsis diagnostics in the future (Chauhan et al.,
2017; Iroh Tam and Bendel, 2017). Automated multiplex
PCR systems can provide pathogen specific identification of
common microorganisms including many organisms found
in neonates such as E.coli and S. aureus in as little as an hour,
(Salimnia et al., 2016) but it is unknown whether all pathogens
are adequately detectable.
Regardless of the method used to detect microorganisms in a
blood sample, sample contamination can mislead diagnosis. To
complicate the issue, when a central venous catheter is used to
draw blood, positive cultures may be due to catheter colonization
(Hall and Lyman, 2006). Some organisms, such as Escherichia
coli, Staphylococcus aureus, and Streptococcus pneumoniae, are
almost always associated with a true infection, while others
are commonly contaminants, such as CoNS and Streptococcus
viridans (Hall and Lyman, 2006). When a common contaminant
is cultured, misdiagnosis is reduced by obtaining and comparing
multiple cultures; and when blood is drawn from a catheter, a
second sample should be drawn percutaneously (Schifman et al.,
1998; Hall and Lyman, 2006). CoNS are the most common blood
culture contaminants, (Hall and Lyman, 2006) but they are also
a prominent causative agent of LOS (Dong and Speer, 2015). In
this study, approximately 54% of cultures positive for CoNS were
identified as true positives, 46% were identified as potentially
contaminated. Additionally, at least 15% of CoNS-positive
cultures were from catheter-drawn blood samples. Distinguishing
between contaminants and pathogens is imperative in these
cases. CoNS cultures cannot simply be completely excluded
from, or completely included in, culture-confirmed cases.
Clinical signs and laboratory results indicating sepsis beyond
blood cultures are commonly used to classify confirmed cases
of sepsis (Bizzarro et al., 2005; Haque, 2005; Wynn et al., 2014;
Zea-Vera and Ochoa, 2015). Incorporating any of these methods
into confirming sepsis retrospectively has shortcomings;
in particular, data are sometimes sparse. It is important to
realize that when laboratory results or clinical signs remain
abnormal but blood cultures are negative, sepsis may still be
suspected and the use of antibiotics may be prolonged. To allow
comparisons with other studies and since blood cultures are the

Neonatal Mortality

As described, patient mortality had statistically significant
increasing trend over the study period for unconfirmed EOS
and LOS and confirmed LOS. For the combined EOS and LOS
cohorts, a logistic regression model estimated a mortality rate
within 35 days of birth of 0.4% at the beginning of the study
period to 8.5% of patients at the end (odds ratio 1.30/year, 95%CI
[1.13, 1.52], p < 0.01). Additionally, the use of cefotaxime was
included in treatment courses for unconfirmed EOS and LOS
at an increasing rate during the study period (Table 4). For
combined EOS and LOS neonates, the inclusion of cefotaxime
within 28 days of birth went from 5.6% of courses to 37.6% of
courses (odds ratio 1.21, 95%CI [1.16, 1.27], p < 0.01) over the
course of the study period.
When mortality was modeled as a function of whether
neonates had exposure to cefotaxime within 28 days of birth,
cefotaxime exposure had a significant impact on mortality
(odds ratio 7.92, 95%CI [3.76, 17.79], p < 0.01). This association
remained when gestational age, birth weight, hospital admission
date-time, blood culture confirmation of sepsis, risk of mortality,
and severity of illness were added to the logistic regression model
as potential confounders (adjusted odds ratio 2.8, 95%CI [1.21,
6.88], p = 0.02).

DISCUSSION
Confirmation of Neonatal Sepsis

Establishing blood culture-confirmed neonatal sepsis is
complicated by the presence of false negative culture results
and culture contamination. False negative cultures are
commonly attributed to low volume of blood or low pathogen
concentrations, which is an inherent problem in the mostly
low body weight newborns with neonatal sepsis (Kellogg et al.,
2000; Dien Bard and McElvania TeKippe, 2016). Additionally,
it is believed by some that exposure to intrapartum antibiotics
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gold standard for the diagnosis of neonatal sepsis, the criteria
for retrospectively confirming neonatal sepsis via a modified
version of CDC guidelines (Horan et al., 2008) within this study
used only culture results.

antibiotic treatment can be ceased after 48 h if cultures remain
negative (Jardine et al., 2006; Durrani et al., 2019) Cantey et
al. demonstrated that when empiric neonatal antibiotic therapy
was set to automatically discontinue after 48 h and continued
therapy was limited to 5 days when cultures were negative,
there was no difference in safety outcomes compared to prior
practices where antibiotics were regularly administered ≥6 days
when cultures were negative (Cantey et al., 2016).
Since the gestational age, birth weight, severity of illness, risk
of mortality, and the ratio of culture confirmed to unconfirmed
cases of neonatal sepsis remained fairly consistent throughout the
study period, it was unexpected that the neonatal sepsis mortality
rate within the University of Utah Hospital system increased over
the study period. In 2006, Clark et al. showed that the concurrent
use of ampicillin and cefotaxime within 3 days of birth rather
than ampicillin with gentamicin had an increased risk of
mortality (Clark et al., 2006). Logistic modeling showed that the
use of cefotaxime within 28 days of birth may be a cause of the
increased neonatal sepsis mortality within the University of Utah
hospital system, even after adjusting for potential confounders.
This conclusion is limited by the retrospective nature of this
study: cefotaxime administration may be a surrogate for some
other unknown factor. Further analysis of the causes of death
and the motivations for prescribing cefotaxime may reveal other
factors that may be responsible for the increased mortality rate.
One potential limitation of this study is that antibiotic therapy
may have been prolonged for neonates with infections other than
sepsis such as pneumonia or meningitis. In our patient cohorts,
there were no neonates that had both negative blood cultures and
positive CSF culture which would suggest neonatal meningitis.
When neonates with any other positive cultures were removed
from the unconfirmed cohorts (see Table 1), the LOT/course
for courses starting ≤3 days of birth reduced from 6.1 to 6.0 for
unconfirmed EOS and the LOT/course for courses starting >3–28
days of birth reduced from 7.8 to 7.5 for unconfirmed LOS. Both
of these differences were insignificant (p > 0.05); therefore, we
believe that the main findings of this study are still supported.
This study has other limitations. Comorbidities and mother’s
characteristics were not accounted for and may affect suspicion
of sepsis and choices in antibiotic treatments. The results of this
study cannot be generalized to other hospitals since epidemiology
and practices are likely to differ from region to region.

Treatments for Neonatal Sepsis

Of neonates treated for EOS in the University of Utah Hospital
system, only 2.3% had blood culture confirmation and there
was a high rate of empiric use of ampicillin and gentamicin.
This type of empiric treatment is common practice in neonatal
intensive care units (NICUs) within the United States. Oliver
et al. reported that within the Pediatric Health Information
System, 92.5% of neonates in a NICU that were administered
antibiotics within three days of birth received ampicillin and/
or gentamicin on the first day of treatment (Oliver et al., 2017).
Cefotaxime appeared to be a preferred choice in therapy for
confirmed EOS with gram-negative infections for the University
of Utah Hospital system.
Empiric treatment for LOS seems to vary more than empiric
treatment for EOS, but within the University of Utah Hospital
system, vancomycin and/or gentamicin were the most common
treatments. In a 2002 survey of 278 neonatology clinicians at 35
hospitals with NICUs, at least 60% prescribed vancomycin as part
of empiric therapy for unconfirmed LOS, commonly combined
with an aminoglycoside (Rubin et al., 2002). Prudent use of
vancomycin has been advised for decades due to the evolution of
vancomycin resistant strains of pathogens (The Hospital Infection
Control Practices Advisory Committee, 1995). There is some
evidence that empiric vancomycin does not improve short-term
mortality or length of stay when neonates are infected with CoNS
(Ericson et al., 2015). Within the University of Utah Hospital
system, there are signs of improvement in the antibiotic stewardship
of vancomycin where the DOT/1,000 PD for vancomycin use was
37.3% lower in unconfirmed compared to confirmed cases of LOS
with a significant reduction in empiric use over time (Table 4).
Rifampin was often combined with vancomycin to treat persistent
CoNS infections within the University of Utah Hospital system—
there is some limited evidence that this strategy is effective (Acar
et al., 1983; Shama et al., 2002; van der Lugt et al., 2010; RodriguezGuerineau et al., 2013).
Neonates with unconfirmed sepsis within the University
of Utah Hospital system were treated for a median of 7 days
LOT IQR (Clark et al., 2006; Liu et al., 2012), which is similar
to, or longer than, treatment lengths for unconfirmed sepsis
in similar studies within the United States and Europe (Patel
et al., 2009; Cantey et al., 2015; Fjalstad et al., 2016). Antibiotic
administration may be prolonged even when cultures are
negative if blood cell counts, C reactive protein levels, or other
diagnostic tests remain abnormal. Continued administration
of antibiotics when cultures are negative appears to be a
common practice. This is in spite of evidence that prolonged
empirical antibiotic administration within neonates (≥5
days) is associated with adverse outcomes such as necrotizing
enterocolitis, prolonged hospital stay, and death (Kuppala
et al., 2011; Ting et al., 2016). Recent studies on the incubation
time for blood cultures in cases of neonatal sepsis suggest that
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TWELVE-YEAR OVERVIEW
Over the past 12 years, the level of empirical treatment remained
high. The major limitations to reduce empirical treatment are
highly variable clinical presentation of sepsis in neonates and low
levels of confirmed sepsis. The development or improvement of
diagnostic tests capable of accurately confirming sepsis within
1–2 h after blood draw is a key factor that will reduce empirical
treatment of neonatal sepsis. One of the possible risk factors
for the development of sepsis in neonates is an underdeveloped
immune defences (Gervassi and Horton, 2014). Recently, it
has been proposed that immune responses in neonates are
suppressed by afterbirth residual myeloid derived suppressor
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cells (MDSCs) (Gervassi and Horton, 2014). MDSCs are a
heterogeneous population of immature myeloid cells capable of
expanding following pathologic conditions such as infections
and cancer. MDSCs have been detected in the blood of septic
patients (Cuenca et al., 2011). The ontogenetic destiny of MDSCs
is to suppress the fetal immune response against the mother.
MDSCs possess the remarkable ability to suppress T, B, and
NK cell functions and by this mean impair protective immune
responses to infectious agents (Rieber et al., 2013; Gervassi et al.,
2014). Presence of these cells in cord blood can potentially serve
as early biomarker of neonatal sepsis. If MDSCs indeed suppress
anti-microbial immunity of neonates, the immune system can be
restored and sepsis development prevented by blocking MDSCs
activity or by differentiation of MDSCs into mature myeloid cells
lacking suppressive activities. This approach may reduce the
rate of neonatal sepsis, empirical use of antibiotics, and increase
survival of preterm babies.

of neonatal sepsis and reevaluating guidelines for appropriate
antibiotic use.
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CONCLUSIONS
In conclusion, the large proportion of unconfirmed to confirmed
neonatal sepsis combined with a high empiric antibiotic
administration rate and high level of exposure indicates an
opportunity to reduce unnecessary antibiotic use in the neonatal
population. This may be accomplished by implementing new
and improved methods for more sensitive and timely diagnosis
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